Restoring either muscle force in a CNM mouse model or DNM2 function in patient‐derived cells is an essential breakthrough towards future gene‐based therapy for dominant centronuclear myopathy. The gene discussed is DNM2; the disease is autosomal dominant centronuclear myopathy.